These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2286 related items for PubMed ID: 9915665

  • 21. Cholesterol and atherosclerosis: a contemporary perspective.
    Kashyap ML.
    Ann Acad Med Singap; 1997 Jul; 26(4):517-23. PubMed ID: 9395824
    [Abstract] [Full Text] [Related]

  • 22. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R, Di Pino A, Ferrara V, Urbano F, Piro S, Rabuazzo AM, Purrello F.
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
    Tenenbaum A, Fisman EZ.
    Cardiovasc Diabetol; 2012 Oct 11; 11():125. PubMed ID: 23057687
    [Abstract] [Full Text] [Related]

  • 25. Lipid-lowering therapy in diabetes mellitus.
    Niemeijer-Kanters SD, Banga JD, Erkelens DW.
    Neth J Med; 2001 May 11; 58(5):214-22. PubMed ID: 11414234
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct 11; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 28. Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus.
    Lee SJ, Sacks FM.
    Am J Cardiol; 2003 Jul 15; 92(2):121-4. PubMed ID: 12860210
    [Abstract] [Full Text] [Related]

  • 29. Current, new and future treatments in dyslipidaemia and atherosclerosis.
    Chong PH, Bachenheimer BS.
    Drugs; 2000 Jul 15; 60(1):55-93. PubMed ID: 10929930
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Pathophysiology of Diabetic Dyslipidemia.
    Hirano T.
    J Atheroscler Thromb; 2018 Sep 01; 25(9):771-782. PubMed ID: 29998913
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM.
    Ann Intern Med; 1996 Oct 01; 125(7):529-40. PubMed ID: 8815751
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z.
    Nutr Metab Cardiovasc Dis; 2013 Sep 01; 23(9):799-807. PubMed ID: 23932901
    [Abstract] [Full Text] [Related]

  • 40. Intensive lipid-lowering strategy in patients with diabetes mellitus.
    Kanters SD, Algra A, de Bruint TW, Erkelens DW, Banga JD.
    Diabet Med; 1999 Jun 01; 16(6):500-8. PubMed ID: 10391399
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 115.